Article
David Brennan, the chief executive of AstraZeneca, will step down on June 1 as the big British pharmaceutical company struggles with competition from makers of generic drugs and the failure of several drug development projects.
Mr. Brennan, 58, who has been in his post for six years, was under some pressure from shareholders to resign because of AstraZeneca’s performance.
Read the full story: http://hcp.lv/IhDj2O
Source: The New York Times
Expert Insights on How Utilization Management Drives Physician Burnout
Finding Health Care Best Practices From Successes Around the World
Evaluating COVID-19 Vaccination Safety in Multiple Sclerosis